NEW YORK (GenomeWeb News) – Intradigm has licensed siRNA technology from the University of Massachusetts Medical School that will help in its RNAi-based therapeutics programs, the company said today.
 
The UMass intellectual property covers “certain efficacy-enhancing structural elements” of siRNA, as well as parameters for structural modifications that will help the company “significantly improve the potency and efficacy of RNAi therapeutics,” Intradigm said.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.